Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

  title={Genetic variation in IL28B and spontaneous clearance of hepatitis C virus},
  author={David L. Thomas and Chloe L. Thio and Maureen P. Martin and Ying Qi and Dongliang Ge and Colm O'huigin and Judith R. Kidd and Kenneth K. Kidd and Salim I. Khakoo and Graeme J Alexander and James J. Goedert and Gregory D Kirk and Sharyne M. Donfield and Hugo R. Rosen and Leslie H. Tobler and Michael P. Busch and John McHutchison and David B. Goldstein and Mary N. Carrington},
  pages={798 - 801}
Hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, with estimates of 4 million HCV-infected individuals in the United States and 170 million worldwide. Most (70–80%) HCV infections persist and about 30% of individuals with persistent infection develop chronic liver disease, including cirrhosis and hepatocellular carcinoma. Epidemiological, viral and host factors have been associated with the differences in HCV clearance or persistence, and studies… 
Insights into the role of interferon lambda in hepatitis C virus infection.
  • H. Barth
  • Biology, Medicine
    Journal of hepatology
  • 2011
IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.
A association between genetic variation in the region of the IL28B gene and treatment outcome in HCV-1 patients and patients who carry the good response variant are two- to three-fold more likely to be cured.
Hepatitis C virus spontaneous clearance: immunology and genetic variance.
Findings of different studies on host immune responses after HCV infection and the association between cytokine gene polymorphisms and the likelihood of HCV clearance are summarized.
The control of immune responses in chronic hepatitis C virus infection
The association of IFNL4 polymorphisms with immune response in the liver in patients with chronic HCV infection and the impact of several genetic polymorphisms on the severity of chronic hepatitis C was investigated.
IL28B and the control of hepatitis C virus infection.
The genetic studies that uncovered the association between IL28B and HCV clearance, the biology of IFN-λ3, the clinical implications of the genetic association, and areas of future research are reviewed.
[The function and application of the IL28B gene in HCV infection and treatment].
The results showed that single nucleotide polymorphisms of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV).
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
The association of the IL28B locus with natural and treatment-associated control of HCV indicates the importance of innate immunity and interferon lambda in the pathogenesis ofHCV infection.
Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?
This review summarizes the data on HCV diversity and the current state of knowledge about the contributions of antibodies, T cells, and host genetic polymorphism in driving HCV evolution in vivo.


Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
The natural history of hepatitis C virus infection: host, viral, and environmental factors.
The results indicate that although HCV infection can be self-limited or associated with ESLD, the majority of adults have persistent viremia without clinically demonstrable liver disease.
Immunology of hepatitis B virus and hepatitis C virus infection
This review assesses recent advances in the understanding of viral hepatitis, contrasts mechanisms of virus–host interaction in acute hepatitis B and hepatitis C, and outlines areas for future studies.
Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection
It is concluded that approximately 85% of people with acute hepatitis C develop persistent viremia, however, acute infections are uncommonly recognized clinically, underscoring the importance of screening individuals at risk.
Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics
Dose- and time-dependent HCV inhibition and kinetics of IFN-λ-mediated signal transducers and activators of transcription (STAT) activation and induction of potential effector genes were distinct from those ofIFN-α.
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
IFN-lambda exhibited dose- and time-dependent HCV inhibition, independent of types I and II IFN receptors and the kinetics of IFN- lambda-mediated signal transducers and activators of transcription (STAT) activation and induction of potential effector genes were distinct from those of IFn-alpha.
Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.
Most of the women with HCV infection 17 years after receiving HCV-contaminated anti-D immune globulin had evidence of slight or moderate hepatic inflammation on liver biopsy, about half had fibrosis, and 2 percent had probable or definite cirrhosis.
Natural history of chronic hepatitis C
Efforts to determine natural history are handicapped by the primary characteristics of the disease, namely that its onset rarely is recognized and its course is prolonged exceedingly, so that at least 20% of chronically infected adults develop cirrhosis within 20 years.